Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

AHT begins equine herpes virus vaccine research
Equine herpes virus causes respiratory disease, abortion or fatal illness in newborn foals.
Charity to design a modified live virus vaccine 

The Animal Health Trust (AHT) has begun research into developing a new vaccine to protect against equine herpes virus (EHV-1).

Overseen by Dr Neil Bryant, the research comes after the AHT became aware of a pressing need for progress towards a new and improved EHV-1 vaccine.

In March, the Newmarket-based charity was called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in Yorkshire and Suffolk. This need led to the development of an Equine Industries EHV Vaccine Steering Group, comprising of world-renowned experts on both human and equine herpes virus.

Chaired by Professor Joe Brownlie of the RVC, the steering group has looked at the existing scientific evidence and agreed the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.

“We’re at the beginning of a very exciting and potentially ground-breaking vaccine development,” said Dr Bryant. “Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs.

“We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1.”

EHV-1 causes respiratory disease, abortion or fatal illness in newborn foals. It also causes neurological disease in adult horses.

Whilst EHV can have severe consequences, there is no vaccine that is licensed to protect against the neurological form of the disease. Existing vaccines do not offer sufficient protection - something that was emphasised in 2016 by the Hertfordshire ‘abortion storm’ in fully vaccinated animals.

“EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world,” said Dr Bryant. “It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the Thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.